Generic Medicine Info
May be taken with or without food.
History of toxic or idiosyncratic agranulocytosis/granulocytopenia, neutropenia, impaired bone marrow function, uncontrolled epilepsy, circulatory collapse, CNS depression of any cause, severe cardiac disorder, circulatory collapse, paralytic ileus, alcoholic or toxic psychosis, drug intoxication. Severe renal and hepatic (including active or progressive liver disease, hepatic failure) impairment. Concomitant use with long-acting depot antipsychotics, alcohol.
Special Precautions
Patient with CV or cerebrovascular disease or conditions predisposing to hypotension, history of or risk factors for seizure, risk or history of QT prolongation, DM, BPH, urinary retention, xerostomia, decreased gastrointestinal motility, visual problems. Smokers. CYP2D6 poor metabolisers. Patients taking strong CYP2D6 inhibitors. Avoid abrupt withdrawal. Renal and hepatic impairment. Elderly (not indicated for use in dementia-related psychosis). Pregnancy and lactation. Patient Counselling This drug may cause seizures, somnolence and motor or sensory instability, if affected, do not drive or operate machinery. Monitoring Parameters Obtain baseline CBC, including ANC (must be ≥1,500/mm3 prior to initiation of treatment to general population and ≥1,000/mm3 in patients with benign ethnic neutropenia prior to initiation of treatment); serum cholesterol, triglycerides, LDL and HDL concentrations; ECG, blood pressure. Monitor for signs and symptoms of neutropenia or infection (e.g. fever, weakness, lethargy, sore throat); myocarditis (e.g. chest pain, tachycardia, palpitations, dyspnoea); bowel function, constipation, mental changes, fever, muscle rigidity.
Adverse Reactions
Significant: Orthostatic hypotension, bradycardia, syncope, seizures, decreased gastrointestinal motility, urinary retention, xerostomia, visual problems, CNS depression, dyslipidaemia, eosinophilia, oesophageal dysmotility/aspiration, extrapyramidal symptoms, risk of fall, fever, hyperglycaemia, QT prolongation, sialorrhoea and drooling, suicidal ideation, temperature regulation disturbance, deep vein thrombosis, pulmonary embolism, weight gain. Cardiac disorders:Tachycardia. Gastrointestinal disorders: Constipation, nausea, vomiting, dyspepsia. Nervous system disorders: Dizziness, insomnia, vertigo, headache. Vascular disorders: Hypertension.
Potentially Fatal: Severe agranulocytosis/neutropenia, myocarditis and cardiomyopathy, hepatotoxicity including hepatic failure, hepatic necrosis and hepatitis, torsade de pointes, cardiac arrest, neuroleptic malignant syndrome, respiratory depression or failure, paralytic ileus, intestinal obstruction, faecal impaction.
Drug Interactions
Enhances the CNS effects of narcotics, antihistamines and benzodiazepines. May reduce therapeutic effect of norepinephrine. Increased plasma level with CYP1A2 inhibitors (e.g. ciprofloxacin, fluvoxamine, enoxacin, oral contraceptives, caffeine). Decreased plasma level with CYP1A2 inducers. Increased risk of neuroleptic malignant syndrome with lithium. Risk of seizures with valproic acid.
CIMS Class
ATC Classification
N05AH02 - clozapine ; Belongs to the class of diazepines, oxazepines and thiazepines antipsychotics.
Disclaimer: This information is independently developed by CIMS based on clozapine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in